Are you Dr. Berdeja?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 81 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
250 25th Ave N
Ste 412
Nashville, TN 37203Phone+1 615-986-7000Fax+1 615-986-7601- Is this information wrong?
Summary
- Dr. Jesus Berdeja, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee, Maryland, and California. He is affiliated with TriStar Centennial Medical Center and Ascension Saint Thomas.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
University of California (San Francisco)Residency, Internal Medicine, 1994 - 1997
Harvard Medical SchoolClass of 1994
Certifications & Licensure
CA State Medical License 1996 - Present
TN State Medical License 2008 - 2025
MD State Medical License 1998 - 2002- American Board of Internal Medicine Hematology
Clinical Trials
- IMGN901 in Combination With Lenalidomide and Dexamethasone Start of enrollment: 2009 Dec 01
- Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy Start of enrollment: 2010 May 01
- Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsCiltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.Myo Htut, Binod Dhakal, Adam D Cohen, Thomas Martin, Jesus G Berdeja, Saad Z Usmani, Mounzer Agha, Carolyn C Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 1
- 3 citationsTime-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.Bruno Paiva, Irene Manrique, Julie Rytlewski, Timothy Campbell, Christian C Kazanecki, Nathan Martin, Larry D Anderson Jr., Jesús G Berdeja, Sagar Lonial, Noopur S Raj...> ;Blood Cancer Discovery. 2023 Sep 1
- Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.Jesus G Berdeja, Adam D Cohen, Thomas Martin, Deepu Madduri, Lida Pacaud, Sundar Jagannath> ;Future Oncology. 2023 Jun 1
- Join now to see all
Press Mentions
Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021- Subcutaneous Bispecific Antibodies Are Effective in Pre-Treated Multiple MyelomaJune 2nd, 2021
- VRd Still Reigns in Newly Diagnosed MyelomaJune 1st, 2020
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Ascension Saint ThomasNashville, Tennessee
TriStar Centennial Medical CenterNashville, Tennessee
